These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
515 related articles for article (PubMed ID: 27129167)
1. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167 [TBL] [Abstract][Full Text] [Related]
2. Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma. Luo Y; Gui R Turk J Haematol; 2020 Nov; 37(4):248-262. PubMed ID: 32812415 [TBL] [Abstract][Full Text] [Related]
4. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib. Tang JX; Chen Q; Li Q; He YH; Xiao D Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728 [TBL] [Abstract][Full Text] [Related]
5. Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma. Zhang ZY; Li YC; Geng CY; Wang HJ; Chen WM Biomed Res Int; 2019; 2019():1575468. PubMed ID: 31915680 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912 [TBL] [Abstract][Full Text] [Related]
8. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Manier S; Liu CJ; Avet-Loiseau H; Park J; Shi J; Campigotto F; Salem KZ; Huynh D; Glavey SV; Rivotto B; Sacco A; Roccaro AM; Bouyssou J; Minvielle S; Moreau P; Facon T; Leleu X; Weller E; Trippa L; Ghobrial IM Blood; 2017 Apr; 129(17):2429-2436. PubMed ID: 28213378 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994 [TBL] [Abstract][Full Text] [Related]
10. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Warnecke-Eberz U; Chon SH; Hölscher AH; Drebber U; Bollschweiler E Tumour Biol; 2015 Jun; 36(6):4643-53. PubMed ID: 25631748 [TBL] [Abstract][Full Text] [Related]
11. Exosomal microRNA panels as biomarkers for hematological malignancies. Moloudizargari M; Hekmatirad S; Mofarahe ZS; Asghari MH Curr Probl Cancer; 2021 Oct; 45(5):100726. PubMed ID: 33752898 [TBL] [Abstract][Full Text] [Related]
12. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Lee YR; Kim G; Tak WY; Jang SY; Kweon YO; Park JG; Lee HW; Han YS; Chun JM; Park SY; Hur K Int J Cancer; 2019 Mar; 144(6):1444-1452. PubMed ID: 30338850 [TBL] [Abstract][Full Text] [Related]
13. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Yan S; Han B; Gao S; Wang X; Wang Z; Wang F; Zhang J; Xu D; Sun B Oncotarget; 2017 Sep; 8(36):60149-60158. PubMed ID: 28947960 [TBL] [Abstract][Full Text] [Related]
14. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Tacchetti P; Pezzi A; Zamagni E; Pantani L; Rocchi S; Zannetti BA; Mancuso K; Rizzello I; Cavo M Haematologica; 2017 Mar; 102(3):e104-e107. PubMed ID: 27909220 [No Abstract] [Full Text] [Related]
15. Exosomal microRNA: a novel biomarker for breast cancer. He Y; Deng F; Yang S; Wang D; Chen X; Zhong S; Zhao J; Tang J Biomark Med; 2018 Feb; 12(2):177-188. PubMed ID: 29151358 [TBL] [Abstract][Full Text] [Related]
16. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Wang N; Wang L; Yang Y; Gong L; Xiao B; Liu X Biochem Biophys Res Commun; 2017 Nov; 493(3):1322-1328. PubMed ID: 28986250 [TBL] [Abstract][Full Text] [Related]
17. Exosome-Transmitted Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101 [TBL] [Abstract][Full Text] [Related]
18. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Hao M; Zang M; Wendlandt E; Xu Y; An G; Gong D; Li F; Qi F; Zhang Y; Yang Y; Zhan F; Qiu L Int J Cancer; 2015 Apr; 136(8):1835-44. PubMed ID: 25220540 [TBL] [Abstract][Full Text] [Related]
19. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Corcoran C; Rani S; O'Driscoll L Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345 [TBL] [Abstract][Full Text] [Related]
20. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]